Benitec Biopharma's Investor Webcast Update
-Management is set to hold an investor webcast, providing insights into the BB-301 Phase 1b/2a Clinical Study. Details are shared below.
-The updated access information for the webcast has superseded previous details shared on October 12.
HAYWARD, Calif. — Benitec Biopharma Inc. (NASDAQ: BNTC), a leader in gene therapy focused on novel genetic medicines, announces the details of an important upcoming investor webcast. During this session, the company's management will provide valuable insights regarding the interim data from the BB-301 Phase 1b/2a Clinical Study.
Webcast Access Information
Title of the Webcast: Interim BB-301 Phase 1b Clinical Study Update
The live presentation of the interim clinical data is scheduled for 8:30 AM EDT. Management will be accompanied by Emily Plowman, PhD, CCC-SLP, FASHA, from The Ohio State University College of Medicine. You can access the event through the following link here.
The replay of the event and the accompanying slides will be made available under the News & Events tab on Benitec's Investor page, ensuring that investors have ongoing access to the information shared.
Understanding Oculopharyngeal Muscular Dystrophy (OPMD)
Oculopharyngeal Muscular Dystrophy, commonly referred to as OPMD, is a rare yet progressive muscle-wasting disease attributed to mutations in the PABPN1 gene. Unfortunately, effective drug therapies are currently lacking. Symptoms include dysphagia, which gradually worsens over time, alongside issues like limb weakness and eyelid drooping. The implications of dysphagia can be dire, potentially leading to chronic choking, aspiration pneumonia, and in severe scenarios, death. Current clinical and surgical interventions are limited and do not tackle the root causes of the disease.
Insights into the BB-301 Therapy
BB-301 represents an innovative approach utilizing a modified AAV9 capsid designed to co-express a codon-optimized version of PABPN1 along with two small inhibitory RNAs targeting the mutation. The combination of these components allows for the silencing of the defective mutant PABPN1 while simultaneously providing a functional protein replacement. This dual action makes BB-301 particularly promising in treating OPMD, an area where traditional therapies have failed to yield effective results.
About Benitec Biopharma, Inc.
Benitec Biopharma Inc. is a pioneer in the field of biotechnology, emphasizing the development of cutting-edge genetic therapies. With its headquarters located in Hayward, California, the company operates on the forefront of gene therapy, particularly through its “Silence and Replace” technology. This proprietary platform effectively employs RNA interference alongside gene therapy methodologies to address chronic and potentially life-threatening conditions like OPMD. For further information about the company and its groundbreaking work, please visit www.benitec.com.
Frequently Asked Questions
What is the purpose of the investor webcast?
The upcoming investor webcast aims to provide updates regarding the BB-301 Phase 1b/2a Clinical Study and share interim data with investors.
When will the investor webcast occur?
The investor webcast is scheduled to take place at 8:30 AM EDT.
Where can I access the replay of the webinar?
The event replay and slides will be available on the News & Events tab of the Benitec Investor page.
What is OPMD?
Oculopharyngeal Muscular Dystrophy is a rare neurological disorder characterized by muscle weakness and swallowing difficulties due to a genetic mutation.
How does BB-301 work?
BB-301 works by silencing the faulty gene associated with OPMD while simultaneously expressing a functional protein, offering a unique treatment approach.
